Login to Your Account



NewCo News

Start-up Dezima Taking on Big Pharma in CETP Inhibition

By Cormac Sheridan
Staff Writer

Wednesday, January 23, 2013
Newly established Dutch start-up Dezima Pharma BV in-licensed what it considers a best-in-class cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (formerly TA-8995), from Osaka, Japan-based Mitsubishi Tanabe Pharma Corp. and is planning to move the cholesterol-lowering drug into a Phase II trial involving more than 400 patients in the coming months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription